Pulmatrix Announces Publication On Physiologically Based Pharmacokinetic Modelling Of Potential Drug-Drug Interactions With PUR1900, Orally Inhaled Itraconazole
Portfolio Pulse from Benzinga Newsdesk
Pulmatrix has announced the publication of a study on the pharmacokinetic modelling of potential drug-drug interactions with PUR1900, an orally inhaled itraconazole. The results indicate a low likelihood of clinically meaningful interactions when PUR1900 is administered with medications contraindicated with oral itraconazole. Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma.
August 23, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulmatrix's study results showing low likelihood of drug-drug interactions with PUR1900 could potentially boost investor confidence in the company's product pipeline.
The study results showing a low likelihood of drug-drug interactions with PUR1900 could potentially reduce regulatory hurdles and increase the chances of the drug's approval. This could have a positive impact on Pulmatrix's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100